Literature DB >> 20066490

Anti-HER2 immunoliposomes for selective delivery of electron paramagnetic resonance imaging probes to HER2-overexpressing breast tumor cells.

Scott R Burks1, Luciana F Macedo, Eugene D Barth, Katherine H Tkaczuk, Stuart S Martin, Gerald M Rosen, Howard J Halpern, Angela M Brodie, Joseph P Y Kao.   

Abstract

Electron paramagnetic resonance (EPR) imaging is an emerging modality that can detect and localize paramagnetic molecular probes (so-called spin probes) in vivo. We previously demonstrated that nitroxide spin probes can be encapsulated in liposomes at concentrations exceeding 100 mM, at which nitroxides exhibit a concentration-dependent quenching of their EPR signal that is analogous to the self-quenching of fluorescent molecules. Therefore, intact liposomes encapsulating high concentrations of nitroxides exhibit greatly attenuated EPR spectral signals, and endocytosis of such liposomes represents a cell-activated contrast-generating mechanism. After endocytosis, the encapsulated nitroxide is liberated and becomes greatly diluted in the intracellular milieu. This dequenches the nitroxides to generate a robust intracellular EPR signal. It is therefore possible to deliver a high concentration of nitroxides to cells while minimizing background signal from unendocytosed liposomes. We report here that intracellular EPR signal can be selectively generated in a specific cell type by exploiting its expression of Human Epidermal Growth Factor Receptor 2 (HER2). When targeted by anti-HER2 immunoliposomes encapsulating quenched nitroxides, Hc7 cells, which are novel HER2-overexpressing cells derived from the MCF7 breast tumor cell line, endocytose the liposomes copiously, in contrast to the parent MCF7 cells or control CV1 cells, which do not express HER2. HER2-dependent liposomal delivery enables Hc7 cells to accumulate 750 μM nitroxide intracellularly. Through the use of phantom models, we verify that this concentration of nitroxides is more than sufficient for EPR imaging, thus laying the foundation for using EPR imaging to visualize HER2-overexpressing Hc7 tumors in animals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20066490      PMCID: PMC4041539          DOI: 10.1007/s10549-009-0715-4

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  32 in total

Review 1.  Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.

Authors:  H M Shepard; G D Lewis; J C Sarup; B M Fendly; D Maneval; J Mordenti; I Figari; C E Kotts; M A Palladino; A Ullrich
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

Review 2.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Authors:  M X Sliwkowski; J A Lofgren; G D Lewis; T E Hotaling; B M Fendly; J A Fox
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

3.  ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer.

Authors:  J Szöllösi; M Balázs; B G Feuerstein; C C Benz; F M Waldman
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

4.  Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases.

Authors:  George N Naumov; Jason L Townson; Ian C MacDonald; Sylvia M Wilson; Vivien H C Bramwell; Alan C Groom; Ann F Chambers
Journal:  Breast Cancer Res Treat       Date:  2003-12       Impact factor: 4.872

Review 5.  Sterically stabilized liposomes.

Authors:  M C Woodle; D D Lasic
Journal:  Biochim Biophys Acta       Date:  1992-08-14

6.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

Authors:  C R King; M H Kraus; S A Aaronson
Journal:  Science       Date:  1985-09-06       Impact factor: 47.728

7.  Serum independent liposome uptake by mouse liver.

Authors:  F Liu; D Liu
Journal:  Biochim Biophys Acta       Date:  1996-01-12

8.  Nitroxide conjugate of a thermally responsive elastin-like polypeptide for noninvasive thermometry.

Authors:  Matthew R Dreher; Martyna Elas; Kazuhiro Ichikawa; Eugene D Barth; Ashutosh Chilkoti; Gerald M Rosen; Howard J Halpern; Mark Dewhirst
Journal:  Med Phys       Date:  2004-10       Impact factor: 4.071

9.  c-erbB2 expression in correlation to other biological parameters of breast cancer.

Authors:  D Marx; A Schauer; C Reiche; A May; L Ummenhofer; A Reles; H Rauschecker; R Sauer; M Schumacher
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

10.  Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms.

Authors:  M H Kraus; N C Popescu; S C Amsbaugh; C R King
Journal:  EMBO J       Date:  1987-03       Impact factor: 11.598

View more
  5 in total

1.  Clearance and biodistribution of liposomally encapsulated nitroxides: a model for targeted delivery of electron paramagnetic resonance imaging probes to tumors.

Authors:  Scott R Burks; Eric A Legenzov; Gerald M Rosen; Joseph P Y Kao
Journal:  Drug Metab Dispos       Date:  2011-07-07       Impact factor: 3.922

2.  Designing Molecular Probes To Prolong Intracellular Retention: Application to Nitroxide Spin Probes.

Authors:  Eric A Legenzov; Sukumaran Muralidharan; Lukas B Woodcock; Gareth R Eaton; Sandra S Eaton; Gerald M Rosen; Joseph P Y Kao
Journal:  Bioconjug Chem       Date:  2016-12-01       Impact factor: 4.774

3.  Co-encapsulating the fusogenic peptide INF7 and molecular imaging probes in liposomes increases intracellular signal and probe retention.

Authors:  Scott R Burks; Eric A Legenzov; Erik W Martin; Changqing Li; Wuyuan Lu; Joseph P Y Kao
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

Review 4.  EPR Everywhere.

Authors:  Joshua R Biller; Joseph E McPeak
Journal:  Appl Magn Reson       Date:  2021-01-24       Impact factor: 0.831

5.  Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer.

Authors:  Armina A Kazi; Rabia A Gilani; Amanda J Schech; Saranya Chumsri; Gauri Sabnis; Preeti Shah; Olga Goloubeva; Shari Kronsberg; Angela H Brodie
Journal:  Breast Cancer Res       Date:  2014-01-29       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.